Analyst Price Targets — GH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:42 am | Luke Sergott | Barclays | $115.00 | $82.21 | TheFly | Guardant Health price target lowered to $115 from $130 at Barclays |
| February 24, 2026 11:40 am | — | Piper Sandler | $130.00 | $94.42 | TheFly | Guardant Health price target raised to $130 from $120 at Piper Sandler |
| February 23, 2026 2:41 pm | — | Raymond James | $129.00 | $97.49 | TheFly | Guardant Health price target raised to $129 from $115 at Raymond James |
| February 20, 2026 12:56 pm | — | Evercore ISI | $110.00 | $106.84 | TheFly | Guardant Health price target raised to $110 from $105 at Evercore ISI |
| February 20, 2026 12:11 pm | — | BTIG | $145.00 | $106.38 | TheFly | Guardant Health price target raised to $145 from $140 at BTIG |
| February 20, 2026 12:09 pm | — | Stifel Nicolaus | $130.00 | $106.38 | TheFly | Guardant Health price target raised to $130 from $120 at Stifel |
| February 20, 2026 11:47 am | — | Canaccord Genuity | $135.00 | $106.38 | TheFly | Guardant Health price target raised to $135 from $125 at Canaccord |
| February 20, 2026 10:04 am | — | Barclays | $130.00 | $106.38 | TheFly | Guardant Health price target raised to $130 from $120 at Barclays |
| February 17, 2026 10:08 am | Catherine Schulte | Robert W. Baird | $120.00 | $104.85 | TheFly | Guardant Health initiated with an Outperform at Baird |
| January 30, 2026 2:02 pm | — | UBS | $175.00 | $111.00 | TheFly | Guardant Health price target raised to $175 from $110 at UBS |
Latest News for GH
Assetmark Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 48.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,718 shares of the company's stock after acquiring an additional 6,461 shares during the quarter. Assetmark Inc.'s holdings in
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors”…
Macro concerns, AI competition, and analyst downgrades drove broad weekly losses across software and cloud stocks, led by Akamai, Okta, and Cloudflare.
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) insider Terilyn Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider owned 20,990 shares of the company's stock, valued
Guardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing. GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth. Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH's revenue momentum and market outperformance.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.